Mind Club

Data as of 11.07.2026 · Primary sources linked · NOT INVESTMENT ADVICE

Disease Pipeline Tools Obesity

Obesity

Programs, trials, and reported weight change for obesity and overweight.

Data as of 11.07.2026

All studies

Exenatide

Effects of GLP-1 RAs on Weight and Metabolic Indicators in Obese Patients

AstraZeneca · Phase 3 · Status n/r · Enrollment 150

NCT03671733

Participants reaching a weight loss threshold

Participants reaching threshold, %

Source: Cited trial source. The denominator is the source figure, when it states one.

No selected arm reports a responder percent.

Show as table
Arm≥5%≥10%≥15%≥20%
Liraglutiden/rn/rn/rn/r
Exenatiden/rn/rn/rn/r
Exenatide Microspheres for Injectionn/rn/rn/rn/r

Not shown

  • Liraglutide: endpoint not reported
  • Exenatide: endpoint not reported
  • Exenatide Microspheres for Injection: endpoint not reported